Algene Achieves Optimal Sampling Milestone on Schizophrenia

MONTREAL, Canada, Dec. 4 --Algene Biotech Companies has anounced that it has reached its first major milestone in conducting research with Janssen Pharmaceuticals. For reaching this point, Algene has acheived an optimal sample for their study, Janssen will pay them an unspecified sum of money. Dr. Dennis Gauvreau, Chairman of the Board and CEO of Algene said that, "the achievement of this milestone confirms our ability to work rapidly and efficiently with the founder populations and to establish optimal sampling for genetic studies...We are actually ahead of our schedule." He added that, "it is more than a matter of sampling from founder populations to obtain significant results in genetic studies. Beyond applying strict clinical and pathological criteria, one must know how to analyze the data. We now expect to conclude by early 1997 the next phase of the schizophrenia program."

According to Dr. Gail Ouellette, also of Algene, "The results obtained are promising for the next phases of our program on schizophrenia and could lead to new developments in the search for the genetic causes of this important disease."

Algene Biotechnologies Corporation works primarily on genetic technology focusing on Alzheimer's disease, schizophrenia, migraine, and Parkinson's disease. Their shares trade under the symbol AGN.B on the Montreal Exchange.

SOURCE Algene Biotechnologies Corporation
/CONTACT: Henri Harland, Vice-president, Corporate Development and Chief Financial Officer, 514-340-3539, or; or Eric Durand, Director, Corporate Development, 514-340-3539, or, both of Algene Biotechnologies Corporation/

[ Home] [News]